Our study found that the expression of FERMT2 and FERMT3 was remarkably correlated with the immune infiltration of six immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells) in LUAD and LUSC, suggesting that FERMT2 and FERMT3 may be potential biomarkers of NSCLC for immune checkpoint blockade therapy. The gene discussed is CD4; the disease is non-small cell lung carcinoma.